Monocyte suppressing action of fenofibrate.
Journal Title: Pharmacological Reports - Year 2005, Vol 57, Issue 3
Abstract
Since atherosclerosis has been proven to be an inflammatory disease, itis obvious that the proper treatment for dyslipidemia should not only correct lipid parameters but alsoinhibit inflammation. Monocytes and monocyte-derived proinflammatory cytokines are widely known to beinvolved in the formation and rupture of the atherosclerotic plaque. The aim of our study was to assessthe effect of fenofibrate, a commonly used hypolipidemic drug, on the release of interleukin 1beta (IL-1beta),interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) by monocytes from patients with combinedhyperlipidemia. Fourteen patients with biochemically confirmed type IIb dyslipidemia who did not respondto a low-fat diet were treated with micronized fenofibrate for 1 month. The control group included 12healthy, normolipidemic, age-matched subjects. To accurately evaluate the levels of the inflammatorycytokines, we excluded patients with any inflammatory disease. Monocytes were isolated from peripheralblood before and after the treatment. IL-1beta, IL-6 and MCP-1 release was measured by enzyme-linkedimmunosorbent assay (ELISA) after lipopolysaccharide stimulation. IL-1beta, IL-6 and MCP-1 levels weresignificantly higher in hyperlipidemic patients compared to the control (143.9 +/- 6.5 vs. 74.4 +/- 4.4pg/ml; 8212 +/- 285 vs. 6110 +/- 170 pg/ml; 19.6 +/- 0.9 vs. 12.3 +/- 0.6 ng/ml, respectively). Thirty-dayfenofibrate treatment decreased the release of IL-1beta by 43% (143.9 +/- 6.5 vs. 86.2 +/- 5.9 pg/ml),of IL-6 by 22% (8212 +/- 285 vs. 6330 +/- 234 pg/ml), and of MCP-1 by 29% (19.6 +/- 0.9 vs. 14.0 +/-0.8 ng/ml). The evaluated cytokines were markedly elevated in patients with type IIb dyslipidemia. Effectivefenofibrate therapy had a significant inhibitory effect on the release of monocyte-derived inflammatorycytokines.
Authors and Affiliations
Bogusław Okopień, Jan Kowalski, Robert Krysiak, Krzysztof Łabuzek, Aldona Stachura-Kułach, Andrzej Kułach, Marek Zieliński, Zbigniew Herman
Keywords
Related Articles
- EP ID EP159747
- DOI -
- Views 104
- Downloads 0
Nisoxetine blocks sodium currents and elicits spinal anesthesia in rats.
Background: Although nisoxetine has been shown to elicit infiltrative cutaneous local anesthesia, the inhibition of voltage-gated Na(+) channels by nisoxetine has not been reported. The aim of this study was to evaluate...
Cytoprotective effect of amifostine in the treatment of childhood neoplastic diseases - a clinical study including the pharmacoeconomic analysis.
Amifostine is an active aminothiol, which has unique properties as a radio-and chemoprotective agent. It has been reported to prevent myelosuppresion and reduce the toxic effects of intensive cancer treatment. In the stu...
Inhibitory effect of albendazole and its metabolites on cytochromes P450 activities in rat and mouflon in vitro.
Cytochromes P450 (CYP) belong to the most important biotransformation enzymes, therefore, their inhibition may lead to serious pharmacological and toxicological consequences. Albendazole (ABZ) is a benzimidazole anthelmi...
No association of three GRIN2B polymorphisms with lithium response in bipolar patients.
We investigated three polymorphisms in the NMDA receptor 2B subunit gene (GRIN2B) as a candidate gene for lithium response involved in glutamatergic neurotransmission. One hundred five bipolar patients treated with lithi...
Abnormalities of the resistance vasculature in hypertension: correction by vasodilator therapy.
The structure of the resistance vessels in patients with essential hypertension is altered, with reduction of the lumen diameter and increase in wall-to-lumen ratio without change inwall mass, known as eutrophic remodell...